Latest news with #CGEN
Yahoo
25-05-2025
- Business
- Yahoo
These Analysts Just Made An Incredible Downgrade To Their Compugen Ltd. (NASDAQ:CGEN) EPS Forecasts
One thing we could say about the analysts on Compugen Ltd. (NASDAQ:CGEN) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon. Shares are up 4.3% to US$1.45 in the past week. Investors could be forgiven for changing their mind on the business following the downgrade; but it's not clear if the revised forecasts will lead to selling activity. Our free stock report includes 2 warning signs investors should be aware of before investing in Compugen. Read for free now. Following the downgrade, the consensus from four analysts covering Compugen is for revenues of US$14m in 2025, implying a painful 49% decline in sales compared to the last 12 months. Losses are supposed to balloon 82% to US$0.28 per share. However, before this estimates update, the consensus had been expecting revenues of US$31m and US$0.12 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts. View our latest analysis for Compugen Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 59% by the end of 2025. This indicates a significant reduction from annual growth of 63% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 17% annually for the foreseeable future. It's pretty clear that Compugen's revenues are expected to perform substantially worse than the wider industry. The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Compugen. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We wouldn't be surprised to find shareholders feeling a bit shell-shocked, after these downgrades. It looks like analysts have become a lot more bearish on Compugen, and their negativity could be grounds for caution. Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for Compugen going out to 2027, and you can see them free on our platform here. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
25-05-2025
- Business
- Yahoo
These Analysts Just Made An Incredible Downgrade To Their Compugen Ltd. (NASDAQ:CGEN) EPS Forecasts
One thing we could say about the analysts on Compugen Ltd. (NASDAQ:CGEN) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon. Shares are up 4.3% to US$1.45 in the past week. Investors could be forgiven for changing their mind on the business following the downgrade; but it's not clear if the revised forecasts will lead to selling activity. Our free stock report includes 2 warning signs investors should be aware of before investing in Compugen. Read for free now. Following the downgrade, the consensus from four analysts covering Compugen is for revenues of US$14m in 2025, implying a painful 49% decline in sales compared to the last 12 months. Losses are supposed to balloon 82% to US$0.28 per share. However, before this estimates update, the consensus had been expecting revenues of US$31m and US$0.12 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts. View our latest analysis for Compugen Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 59% by the end of 2025. This indicates a significant reduction from annual growth of 63% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 17% annually for the foreseeable future. It's pretty clear that Compugen's revenues are expected to perform substantially worse than the wider industry. The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Compugen. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We wouldn't be surprised to find shareholders feeling a bit shell-shocked, after these downgrades. It looks like analysts have become a lot more bearish on Compugen, and their negativity could be grounds for caution. Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for Compugen going out to 2027, and you can see them free on our platform here. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
20-05-2025
- Business
- Yahoo
Bank Hapoalim BM (BKHYY) Q1 2025 Earnings Call Highlights: Strong Profit Growth Amid ...
Return on Equity: 16.4% for the first quarter. Net Profit: NIS2.4 billion, up 25% versus the corresponding quarter. Earnings Per Share (EPS): NIS1.83. Cost to Income Ratio: 35%. Credit Growth: 2.7% in the last quarter, 10.8% in the last 12 months. Total Income Growth: 3.2% versus the fourth quarter, 11.8% versus last year. CET1 Ratio: 11.74%. NPL Ratio: Dropped to 0.52%. Liquidity Coverage Ratio (LCR): 128%. Financing Income Growth: 2.3% in the quarter. Fees Growth: 6.2% in the last quarter, 9.2% in the last 12 months. Operating and Other Expenses: Dropped by 29.1% compared to the previous quarter. Provision for Credit Losses: NIS262 million or 0.23% of the credit book. Dividend Distribution: NIS720 million cash dividend, NIS0.55 per share, and NIS250 million share buyback. GDP Growth: 3.4% annual rate in the first quarter. Inflation: 3.6%. Warning! GuruFocus has detected 3 Warning Signs with CGEN. Release Date: May 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Bank Hapoalim BM (BKHYY) reported a strong return on equity of 16.4% for the first quarter, indicating robust profitability. Net profit increased by 25% compared to the corresponding quarter, showcasing significant financial growth. The bank achieved a cost-to-income ratio of 35%, reflecting efficient cost management. Credit growth was recorded at 2.7% for the last quarter and 10.8% over the last 12 months, driven by demand across various segments. The CET1 capital ratio stood at 11.74%, well above the minimum regulatory requirement, indicating a strong capital position. The bank recorded a special war tax expense, which impacted overall profitability. Provision for credit losses amounted to NIS262 million, reflecting potential impacts from economic and political uncertainties in Israel. The dividend payout ratio is capped at 40% due to ongoing geopolitical uncertainties, limiting shareholder returns. Operating and other expenses were previously high due to a NIS597 million expense for an early retirement plan. The economic environment remains uncertain, with inflation at 3.6% and potential risks from geopolitical tensions affecting future performance. Q: You mentioned the current limitations regarding dividends and buybacks. When might the Bank of Israel lift these restrictions, and what conditions need to change for this to happen? A: The Bank of Israel currently caps the dividend payout ratio at 40% due to geopolitical uncertainties. The lifting of these restrictions depends on a reduction in these uncertainties and improved economic performance. The Bank of Israel evaluates the situation quarterly, so the timeframe for changes is uncertain. Q: Given the current geopolitical situation, do you expect to maintain the same level of loan growth in the coming quarters? A: We achieved a 2.7% growth this quarter, and our guidance suggests an average annual growth of 7% for 2025 and 2026, based on GDP and inflation trends. If the economy performs well, we are prepared to seize opportunities, supported by our strong capital and liquidity positions. Q: Can you provide more details on the factors driving your financing income growth? A: Financing income grew by 2.3% this quarter, driven by credit book growth, asset portfolio repricing, duration extension, and a higher CPI contribution. This growth is sustainable even without the CPI effect. Q: How has the geopolitical environment affected your credit quality metrics? A: Despite the geopolitical challenges, our credit quality has improved, with the NPL ratio dropping to 0.52%. The allowance for credit losses increased to NIS8.1 billion, primarily due to collective allowances reflecting potential economic impacts. Q: What are your expectations for the macroeconomic environment and its impact on your operations? A: The GDP expanded at an annual rate of 3.4% in the first quarter, with inflation at 3.6%. The labor market remains tight, and market expectations suggest potential interest rate cuts by year-end. These factors position us well for continued strong performance. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline
Cash Balance: Approximately $103.7 million as of March 31, 2025. Revenue: Approximately $2.3 million for Q1 2025, compared to $2.6 million in Q1 2024. R&D Expenses: Approximately $5.8 million for Q1 2025, compared to $6.4 million in Q1 2024. G&A Expenses: Approximately $2.4 million for both Q1 2025 and Q1 2024. Net Loss: Approximately $7.2 million or $0.08 per share for Q1 2025, compared to $7.3 million or $0.08 per share in Q1 2024. Cash Runway: Expected to fund operating plans into 2027. Warning! GuruFocus has detected 3 Warning Signs with CGEN. Release Date: May 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Compugen Ltd (NASDAQ:CGEN) has initiated a sub-trial for their anti-PVRIG antibody COM701 in ovarian cancer, targeting an unmet medical need. The company has a strong cash position with a runway extending into 2027, supporting their clinical and research activities. Compugen Ltd (NASDAQ:CGEN) is advancing its early-stage and clinical immuno-oncology pipeline, focusing on innovative therapies. Partnership with AstraZeneca is progressing, with multiple Phase 3 trials initiated, potentially leading to significant revenue opportunities. The company is exploring novel mechanisms of action in their early-stage pipeline, aiming to enhance anticancer immunity. Revenues for the first quarter of 2025 decreased compared to the same period in 2024. The company reported a net loss of approximately $7.2 million for the first quarter of 2025. There is uncertainty in the TIGIT landscape, with previous Phase 3 failures impacting market sentiment. The success of Compugen Ltd (NASDAQ:CGEN)'s TIGIT program is contingent on positive outcomes from upcoming Phase 3 trials. The competitive landscape in ovarian cancer is evolving, with new therapies potentially impacting Compugen Ltd (NASDAQ:CGEN)'s strategy. Q: Merck's KEYNOTE-B96 Phase 3 study in pembrolizumab for platinum-resistant ovarian cancer was successful. How might this impact your strategy in ovarian cancer? A: Michelle Mahler, Chief Medical Officer: The study is in a different setting, but it shows benefit from adding an immune checkpoint inhibitor. If our study demonstrates activity, it could open opportunities to combine COM701 in broader populations. Q: What is your interpretation of Roche's SKYCRAPER-01 data, and how does it affect your confidence in TIGIT antagonism? A: Eran Ophir, Vice President - Research, Drug Discovery: Despite the failure, we see numerical activity in TIGIT trials. The Fc active format may have contributed to high discontinuation rates. We believe Fc inactive antibodies, like ours, may offer safety and efficacy advantages. Q: Do you plan to collect data on tumor microenvironment features in the COM701 study? What PFS benefit would be clinically meaningful in the maintenance setting? A: Michelle Mahler, Chief Medical Officer: We will collect data on the tumor microenvironment but won't disclose details. An improvement of around three months in progression-free survival would be clinically meaningful. Q: Have you observed activity of COM701 in PD-L1 positive patients, and what are your thoughts on PD-1 VEGF bispecifics? A: Michelle Mahler, Chief Medical Officer: We see activity in both PD-L1 positive and negative patients. Eran Ophir, Vice President - Research, Drug Discovery: VEGF increases T cell infiltration, complementing PVRIG biology. Fc inactive TIGIT may be preferable for combinations due to safety concerns. Q: What are your thoughts on the potential synergy between TIGIT, PD-1, and VEGF inhibitors? A: Eran Ophir, Vice President - Research, Drug Discovery: VEGF can enhance T cell infiltration, aligning with PVRIG biology. While we haven't published data, combining with Fc inactive TIGIT could be advantageous due to safety profiles. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
20-05-2025
- Business
- Yahoo
Bank Hapoalim BM (BKHYY) Q1 2025 Earnings Call Highlights: Strong Profit Growth Amid ...
Return on Equity: 16.4% for the first quarter. Net Profit: NIS2.4 billion, up 25% versus the corresponding quarter. Earnings Per Share (EPS): NIS1.83. Cost to Income Ratio: 35%. Credit Growth: 2.7% in the last quarter, 10.8% in the last 12 months. Total Income Growth: 3.2% versus the fourth quarter, 11.8% versus last year. CET1 Ratio: 11.74%. NPL Ratio: Dropped to 0.52%. Liquidity Coverage Ratio (LCR): 128%. Financing Income Growth: 2.3% in the quarter. Fees Growth: 6.2% in the last quarter, 9.2% in the last 12 months. Operating and Other Expenses: Dropped by 29.1% compared to the previous quarter. Provision for Credit Losses: NIS262 million or 0.23% of the credit book. Dividend Distribution: NIS720 million cash dividend, NIS0.55 per share, and NIS250 million share buyback. GDP Growth: 3.4% annual rate in the first quarter. Inflation: 3.6%. Warning! GuruFocus has detected 3 Warning Signs with CGEN. Release Date: May 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Bank Hapoalim BM (BKHYY) reported a strong return on equity of 16.4% for the first quarter, indicating robust profitability. Net profit increased by 25% compared to the corresponding quarter, showcasing significant financial growth. The bank achieved a cost-to-income ratio of 35%, reflecting efficient cost management. Credit growth was recorded at 2.7% for the last quarter and 10.8% over the last 12 months, driven by demand across various segments. The CET1 capital ratio stood at 11.74%, well above the minimum regulatory requirement, indicating a strong capital position. The bank recorded a special war tax expense, which impacted overall profitability. Provision for credit losses amounted to NIS262 million, reflecting potential impacts from economic and political uncertainties in Israel. The dividend payout ratio is capped at 40% due to ongoing geopolitical uncertainties, limiting shareholder returns. Operating and other expenses were previously high due to a NIS597 million expense for an early retirement plan. The economic environment remains uncertain, with inflation at 3.6% and potential risks from geopolitical tensions affecting future performance. Q: You mentioned the current limitations regarding dividends and buybacks. When might the Bank of Israel lift these restrictions, and what conditions need to change for this to happen? A: The Bank of Israel currently caps the dividend payout ratio at 40% due to geopolitical uncertainties. The lifting of these restrictions depends on a reduction in these uncertainties and improved economic performance. The Bank of Israel evaluates the situation quarterly, so the timeframe for changes is uncertain. Q: Given the current geopolitical situation, do you expect to maintain the same level of loan growth in the coming quarters? A: We achieved a 2.7% growth this quarter, and our guidance suggests an average annual growth of 7% for 2025 and 2026, based on GDP and inflation trends. If the economy performs well, we are prepared to seize opportunities, supported by our strong capital and liquidity positions. Q: Can you provide more details on the factors driving your financing income growth? A: Financing income grew by 2.3% this quarter, driven by credit book growth, asset portfolio repricing, duration extension, and a higher CPI contribution. This growth is sustainable even without the CPI effect. Q: How has the geopolitical environment affected your credit quality metrics? A: Despite the geopolitical challenges, our credit quality has improved, with the NPL ratio dropping to 0.52%. The allowance for credit losses increased to NIS8.1 billion, primarily due to collective allowances reflecting potential economic impacts. Q: What are your expectations for the macroeconomic environment and its impact on your operations? A: The GDP expanded at an annual rate of 3.4% in the first quarter, with inflation at 3.6%. The labor market remains tight, and market expectations suggest potential interest rate cuts by year-end. These factors position us well for continued strong performance. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
